Krux
March 6, 2026
Science Corp Raises $230M for Retinal Implant at $1.5B Valuation
Published: March 6, 2026 at 12:34 AM
Updated: March 6, 2026 at 12:34 AM
100-word summary
Science Corp closed a $230M Series C for its PRIMA retinal implant, hitting a $1.5B valuation and bringing total funding to $490M. The brain-computer interface startup plans to launch first in Germany with a CE mark expected mid-2026, while FDA talks continue stateside. Here's the signal: investors are betting on near-term commercialization, not decades-away moonshots. Trial data from 47 patients showed 80% gained meaningful vision improvement, and the company already employs 150 people. Unlike most brain-implant ventures stuck in research mode, Science Corp is racing to get a product on the market this year. The BCI industry's timeline just got a lot shorter.
What happened
Science Corp closed a $230M Series C for its PRIMA retinal implant, hitting a $1.5B valuation and bringing total funding to $490M. The brain-computer interface startup plans to launch first in Germany with a CE mark expected mid-2026, while FDA talks continue stateside. Here's the signal: investors are betting on near-term commercialization, not decades-away moonshots. Trial data from 47 patients showed 80% gained meaningful vision improvement, and the company already employs 150 people. Unlike most brain-implant ventures stuck in research mode, Science Corp is racing to get a product on the market this year.
Why it matters
The BCI industry's timeline just got a lot shorter.